Fluconazole Susceptibilities of Bloodstream Candidasp. Isolates as Determined by National Committee for Clinical Laboratory Standards Method M27-A and Two Other Methods

ABSTRACT The in vitro activity of fluconazole against 143Candida spp. obtained from the bloodstreams of 143 hospitalized patients from 1995 to 1997 was studied. Susceptibility tests were carried out by two macrodilution methods, the M27-A and a modified M27-A method (0.165 M, pH 7/morpholinepropanesulfonic acid-buffered RPMI 1640 medium supplemented with 20 g ofd-dextrose per liter), and by the agar diffusion method (with 15-μg fluconazole [Neo-Sensitab] tablets). With 2 μg of fluconazole per ml, 96.92% of 65 C. albicans isolates, 86.2% of 58 C. parapsilosis isolates 7 of 8 C. tropicalis isolates, and 1 of 6 C. glabrata isolates were inhibited. Only one strain of C. albicans and one strain of C. tropicalis were resistant. The agreement between the two macrodilution methods was greater than 90% within ±2 log2 dilutions for all strains except C. glabrata (83.3%) and C. tropicalis(87.5%). Generally, MICs were 1 log2 dilution lower in glucose-supplemented RPMI 1640 medium. No correlation between zone sizes and MICs was found. All strains susceptible by the diffusion test were susceptible by the dilution method, but the converse was not necessarily true. Interestingly, inhibition zones were smaller forC. albicans, for which the geometric mean MIC was 0.29 μg/ml and the mean inhibition zone diameter was 25.7 mm, while for C. parapsilosis the geometric mean MIC was 0.96 μg/ml and the mean inhibition zone diameter was 31.52 mm. In conclusion, the two macrodilution methods give similar results. The modified M27-A method with 2% dextrose has the advantage of shortening the incubation time and simplifying the endpoint determination.

[1]  E. Anaissie,et al.  Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[2]  J. Billé,et al.  Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group. , 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.

[3]  S. Unal,et al.  In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates , 1997, Antimicrobial agents and chemotherapy.

[4]  H. Hayakawa,et al.  T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations , 1997, Antimicrobial agents and chemotherapy.

[5]  A. Barry,et al.  Fluconazole disk diffusion procedure for determining susceptibility of Candida species , 1996, Journal of clinical microbiology.

[6]  G. Gilbert,et al.  Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique. , 1996, The Journal of antimicrobial chemotherapy.

[7]  J. Martínez-Suárez,et al.  Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans , 1995, Journal of clinical microbiology.

[8]  W. Jarvis Epidemiology of nosocomial fungal infections, with emphasis on Candida species. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Larocco,et al.  Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period , 1994, Antimicrobial Agents and Chemotherapy.

[10]  J. Martínez-Suárez,et al.  Improved medium for fluconazole susceptibility testing of Candida albicans , 1994, Antimicrobial Agents and Chemotherapy.

[11]  A. Bjørneklett,et al.  Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group , 1993, Antimicrobial Agents and Chemotherapy.

[12]  F. Mandelli,et al.  Fungemia in Patients with Leukemia , 1993, The American journal of the medical sciences.

[13]  T. Walsh,et al.  Standardized susceptibility testing of fluconazole: an international collaborative study , 1992, Antimicrobial Agents and Chemotherapy.

[14]  S. Clissold,et al.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.

[15]  J. Galgiani,et al.  Collaborative investigation of variables in susceptibility testing of yeasts , 1990, Antimicrobial Agents and Chemotherapy.

[16]  R. Payne,et al.  Yeasts: Characteristics and Identification , 1983 .

[17]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.